Dapsone-induced peripheral neuropathy.
A young man with dermatitis herpetiformis developed fatigue and neurologic complaints 4 years after he began oral dapsone therapy. Neurologic examination and nerve conduction studies confirmed the presence of a combined motor and sensory peripheral neuropathy. The symptomatic improvement reported by the patient was supported by improvement in the nerve conduction studies after cessation of dapsone therapy. Substitution of sulfapyridine did not adversely affect the resolution of his neuropathy.
D000284:Administration, Oral; D000328:Adult; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects*; D003874:Dermatitis Herpetiformis / Q000188:drug therapy; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy; D011241:Prednisone / Q000008:administration & dosage; D013427:Sulfapyridine / Q000008:administration & dosage; D013997:Time Factors; D014805:Vitamin B 12 / Q000008:administration & dosage; D014815:Vitamins / Q000627:therapeutic use
D014815:Vitamins; D003622:Dapsone; D014805:Vitamin B 12; D011241:Prednisone; D013427:Sulfapyridine